The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Machine learning–based liquid biomarker analysis from the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) gemcitabine/nab-paclitaxel in resectable PDAC (rPDAC).
 
Thomas Seufferlein
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Falk Foundation; MSD Oncology; Pierre Fabre; SERVIER; Takeda
Consulting or Advisory Role - BioNTech SE; Boehringer Ingelheim; Cantargia AB; Mirati Therapeutics; Olympus Medical Systems; Pierre Fabre; Scandion Oncology; SERVIER
Research Funding - Lilly/ImClone (Inst)
Travel, Accommodations, Expenses - Takeda
 
Anton Lahusen
No Relationships to Disclose
 
Martina Kirchner
No Relationships to Disclose
 
Mohamed Jarboui
No Relationships to Disclose
 
Klaus Kluck
No Relationships to Disclose
 
Sarah Wisser
No Relationships to Disclose
 
Waldemar Uhl
No Relationships to Disclose
 
Marko Kornmann
No Relationships to Disclose
 
Hana Algül
No Relationships to Disclose
 
Helmut Friess
No Relationships to Disclose
 
Jasmin Schuhbaur
No Relationships to Disclose
 
Alexander Kleger
No Relationships to Disclose
 
Lukas Perkhofer
Consulting or Advisory Role - AstraZeneca; SERVIER
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jan Budczies
No Relationships to Disclose
 
Margaret Tempero
Honoraria - CPRIT
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Pfizer; ElmediX; Geron; Global Bio Access Fund; Guardant Health; Immodulon Therapeutics; IPSEN Biopharma, Inc.; Merus NV; Mirati Therapeutics; PEPTOMYC; Regeneron; RenovoRx
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb
 
Anke Reinacher-Schick
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; MCI Group; Merck Serono; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Aurikamed; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen-Cilag; Merck Serono; MSD; Pierre Fabre; Roche; Servier
Research Funding - AIO-Studien (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); AstraZeneca (Inst); BioNTech (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Lilly (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; MSD; Pierre Fabre; Roche
 
Albrecht Stenzinger
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; Incyte; Janssen; Lilly; MSD; Novartis; SERVIER; Takeda; Thermo Fisher Scientific
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; MSD; Novartis; Roche; SERVIER; Thermo Fisher Scientific
Research Funding - Bayer; Bristol-Myers Squibb; Chugai Pharma; Incyte
 
Andrea Tannapfel
No Relationships to Disclose
 
Tim Eiseler
No Relationships to Disclose
 
Thomas Ettrich
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Takeda
Research Funding - Baxalta/Shire; Lilly (Inst)
Travel, Accommodations, Expenses - Ipsen; Lilly